137 candidate vaccines in clinical evaluation ID Vaccine platform acronym Vaccine platform description Type of candidate vaccine Route of administration Developers Phase Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 1 IV Inactivated virus CoronaVac; SARS-CoV-2 vaccine (inactivated) IM Sinovac Research and Development Co., Ltd Phase 4 NCT04383574 NCT04754698** NCT04456595 NCT04756830 […]
Guangdi Li1 and Erik De Clercq2 1 Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China. 2 Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. https://doi.org/10.1038/d41573-020-00016-0 Supplementary Table 1 | Summary of antiviral compounds against human coronaviruses Virus-based treatment strategies 2019-nCoV;Influenza RdRp Favipiravir […]
AbbVie Treatment: Kaletra® (also marketed as Aluvia; lopinavir/ritonavir) Type: HIV-1 protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and children 14 days old and older. Status: China’s National Health Commission authorized Kaletra to treat pneumonia caused by SARS-CoV-2, AbbVie announced on January 27. AbbVie has donated RMB 10 million ($1.4 […]
1. Introduction COVID-19, a novel pathogenic coronavirus (2019-nCoV or SARS-CoV2) induced disease, emerged in China and spread globally rapidly. GeneMedi produces kinds of recombinant 2019 nCoV(SARS2 coronavirus) antigens as shown below: Nucleocapsid(N protein), Spike(S protein), RBD, S1+S2 ECD, Envelope (E protein), 3C-like Proteinase. All the recombinant proteins of 2019 nCoV are suitable for in functional […]
Content index About Pre-made gene ORF plasmids for 2019 nCoV (SARS2 coronavirus, COVID-19) COVID-19, a novel pathogenic coronavirus (2019-nCoV or SARS-CoV2) induced disease, emerged in China and spread globally rapidly. GeneMedi offers pre-made gene ORF plasmids for 2019 nCoV (SARS2 coronavirus, COVID-19) as shown below: N protein(Nucleocapsid), S protein(Spike, full lenth), S1 protein(Spike), S protein […]
Content index Introduction of GeneMedi’s COVID-19 Recombinant Antigens reagents COVID-19, a novel pathogenic coronavirus (2019-nCoV or SARS-CoV2) induced disease, emerged in China and spread globally rapidly. GeneMedi produces kinds of recombinant 2019 nCoV (SARS2 coronavirus) antigens as shown below: Nucleocapsid (N protein), Spike(S protein), RBD, S1+S2 ECD, Envelope (E protein), 3C-like Proteinase (also named Mpro, […]
Full-text Download Author:Xiaolong Cai1. Hanbio Research Center, Hanbio Tech Co. Ltd., Shanghai, P.R. China (www.hanbio.net)2. R&D Center, GeneMedi Co.Ltd., Shanghai, P.R. China (www.genemedi.com) Abstract:COVID-19, a novel pathogenic coronavirus emerged in China and spread globally rapidly. COVID-19 shares above 85% identity in genome with SARS-CoV. Patients infected by COVID-19 and SARS-CoV also reveal similar clinical characteristics. Here […]
Interim Laboratory Guidance Version Download 2019 Wuhan Novel coronavirus, (2019-nCoV by WHO), is also known as Wuhan coronavirus, Wuhan seafood market pneumonia virus and Wuhan pneumonia, is a positive-sense, single-stranded RNA coronavirus first reported in 2019. The virus was genomically sequenced after nucleic acid testing on a positive patient sample in a patient with pneumonia during the 2019–2020 Wuhan pneumonia outbreak. On 20 January 2020, human-to-human transmission was confirmed […]
Lentivirus Protocol Download Cell therapy is a kind of medicine aiming to cure disease or alleviate disease symptoms via direct infusion or transplantation of cells, which can be autologous or allogeneic. With several decades’ development and optimization, immuno-oncology cells (such as T cells, nature killer cells, etc.), stem cells (embryonic stem cells, induced pluripotent stem […]
Lentivirus Protocol Download Cell therapy is a kind of medicine aiming to cure disease or alleviate disease symptoms via direct infusion or transplantation of cells, which can be autologous or allogeneic. With several decades’ development and optimization, immuno-oncology cells (such as T cells, nature killer cells, etc.), stem cells (embryonic stem cells, induced pluripotent stem […]
